Drugs Made In America Acquisition II (NASDAQ:DMII) Stock Price Up 0.2% – Time to Buy?

Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) rose 0.2% on Thursday . The stock traded as high as $10.19 and last traded at $10.17. 4,679 shares traded hands during trading, a decline of 96% from the average daily volume of 110,591 shares. The stock had previously closed at $10.15.

Analyst Upgrades and Downgrades

Several brokerages recently commented on DMII. Weiss Ratings raised Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a report on Tuesday. Wall Street Zen raised Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Drugs Made In America Acquisition II Stock Performance

The stock’s fifty day simple moving average is $10.11 and its 200 day simple moving average is $10.05.

Drugs Made In America Acquisition II (NASDAQ:DMII) last released its quarterly earnings results on Friday, August 14th. The company reported $0.07 earnings per share for the quarter.

Hedge Funds Weigh In On Drugs Made In America Acquisition II

Several institutional investors and hedge funds have recently bought and sold shares of the stock. ABC Arbitrage SA purchased a new stake in Drugs Made In America Acquisition II in the fourth quarter worth about $396,000. Wealthspring Capital LLC purchased a new position in shares of Drugs Made In America Acquisition II during the 4th quarter valued at about $4,049,000. HighTower Advisors LLC purchased a new position in shares of Drugs Made In America Acquisition II during the 4th quarter valued at about $7,817,000. Geode Capital Management LLC bought a new position in shares of Drugs Made In America Acquisition II during the 4th quarter valued at approximately $265,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new position in shares of Drugs Made In America Acquisition II during the 4th quarter valued at approximately $3,960,000.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank?check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply?chain resiliency and related healthcare operations in the United States.